We recently read the article by Coilly et al. [1], who used protease inhibitors to treat recurrent hepatitis C after liver transplantation. They described that the side effects, including severe infection and anemia, frequently led to treatment discontinuation or significant dose reduction. They also reported a low sustained viral response (SVR) rate to their telaprevir-based treatment [1]. In our patients, plasma cell hepatitis (PCH) was a frequent complication. We describe our experience of telaprevir-based therapy for hepatitis C after liver transplantation, with special references to PCH.
Case #2 had increased liver enzymes at 31 weeks after completing triple therapy with ETR. Because a biopsy showed moderate PCH, the patient was treated similarly to Case #1. The outcomes were satisfactory, with normalization of liver enzymes and SVR 12 .
Cases #3 and #4 had increased liver enzymes during PegIFNa2b and ribavirin therapy. Because biopsies showed mild PCH and only a short time had elapsed after completing telaprevir, these patients were prescribed 5 mg/day of oral prednisolone, with satisfactory outcomes with SVR 12 . PCH is characterized by the infiltration of plasma cells around the portal triads, without apparent bile duct injury or endotheliitis. PCH was also referred to as de novo autoimmune hepatitis after liver transplantation [4] . However, Levitsky et al. [5] recently proposed the term interferon-induced graft dysfunction (IGD) for interferon-induced liver graft damage pathologically characterized by PCH, ACR, chronic rejection, or a combination of these. One of their most important findings was the poor survival of grafts with IGD and SVR, even compared with grafts without SVR. PCH, a common feature of IGD, is a serious complication during or after interferon-based treatment for hepatitis C after liver transplantation.
Levitsky et al. [5] reported that no prior interferon treatment, the use of PegIFNa-2a, and features consistent with PCH in pretreatment liver biopsy were risk factors for PCH. However, Fiel et al. [5] reported that 80% of patients with PCH had a recent lowering of their immunosuppression protocol. Kugelmas et al. [6] reported that the clearance of hepatitis C virus improved hepatic microsomal function, resulting in lower immunosuppression levels [6] , and that the mean decrease in the calcineurin inhibitor level after viral clearance was 32% in responders and <1% in non-responders. In fact, in Cases #3 and #4 the CsA level declined spontaneously, by 50-60%, after viral clearance, which probably caused PCH. However, the CsA levels were stable (100-150 ng/ml) in Cases #1 and #2. It is likely that the loss of the therapeutic target increased the sensitivity of the host's immune system to the transplanted graft [3] . In triple therapy including telaprevir, which has potent viral clearance activity and strong interference with calcineurin inhibitor metabolism, there might be more chances to have interferon induced PCH and IGD.
Although the accumulation of more cases is essential, we wish to highlight the possibility of PCH in patients treated with protease inhibitors for hepatitis C after liver transplantation. Because of the potential severity of PCH, close monitoring and careful adjustment of the CsA level is necessary at the start of treatment and after viral clearance. Hepatologists should be aware of this complication, and its diagnosis and treatment.
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To the Editor:
We much appreciate Dr Ikegami and colleagues' comments on our study on the use of a first generation protease inhibitor-based regimen to treat hepatitis C (HCV) recurrence after liver transplantation (LT) [1] . One comment concerned the lack of occurrence of plasma cell hepatitis (PHC) in our series of 37 patients. Dr Ikegami reported on 9 patients treated with telaprevir (TVR), peginterferon a2b (PegIFN) and ribavirin (RBV) in a context of HCV recurrence after living donor LT. PHC occurred in 33.3% of patients (3/9) during triple therapy, compared with 6.7% (7/105) during standard PegIFN/RBV. We have developed some arguments to explain the difference between these two different findings. A low immunosuppressive regimen is a risk factor for the development of PCH [2] . All patients in Dr Ikegami's letter received cyclosporine (CsA) ± mycophenolate mofetil (MMF). Data concerning targeted trough blood concentrations (TBC) of CsA, and the delay between triple therapy and LT, were lacking. All PHC cases reported by Dr Ikegami occurred after the discontinuation of TVR (weeks 21, 31, and 12). Despite biweekly monitoring, the mean CsA TBC in patient 3 was low after week 12 (from 53 to 86 ng/ml). Drug-drug interactions between PI and calcineurin inhibitors have always been the main challenge when using PI after LT. In the first instance, we focused on the PI initiation period to demonstrate its feasibility in terms of practical management [3] . We also looked carefully at the time of PI discontinuation. In our study, TBC were monitored daily and CsA doses were also adjusted daily to reach the target range. It was necessary to increase the CsA doses by 47% after TVR discontinuation [1] . In this context, HCV clearance might have an impact on PHC occurrence with triple therapy, but drug-drug interactions are more likely to be responsible for the excess risk found by Ikegami et al.
One observation in Dr Ikegami's letter was particularly surprising, and concerned the favorable outcome of PHC in all patients. This contrasted with the usually poor prognosis of PHC in a context of HCV recurrence. According to Fiel et al., patients who were not treated or were receiving corticosteroids had a negative outcome. Cirrhosis was seen to develop in 60% of patients (4). According to Dr Ikegami, patients 1 and 2 were treated with steroid pulses and an increase in or addition of mycophenolate mofetil (MMF). For patient 1, we could hypothesize that acute cellular rejection (ACR) justified such a treatment. And as for patient 3, MMF and low-dose corticosteroids (5 mg) were added to CsA.
The prevalence of PHC may vary, depending on the diagnosis criteria applied. Most studies on PHC have considered that this diagnosis is based on three criteria: (1) abnormality of liver tests, (2) increased levels of immunoglobulin G and/or specific antibodies of auto-immune hepatitis, (3) compatible histological features. Dr Ikegami does not mention any serological data. Furthermore, we have some concerns about the histological findings. The authors considered that the diagnosis was based on the presence of centrilobular and portal necrosis and a prominent (>30%) plasma cell (PC) aggregation, as previously described by Fiel et al. [4] . In patient 1, PHC was associated with ACR. The differential diagnosis between these entities can be difficult. In severe ACR, a severe portal necro-inflammatory activity may mimic hepatitis. The infiltrate may be made up of PC, but without proper PCH. In order to clarify the histological features of PCH, we recently reported on a scoring system based on centrilobular changes such as necro-inflammatory activity (NIA) and the centrilobular PC ratio. The positive predictive value of the association of severe centrilobular NIA and a PC ratio of up to 30% was >90% [5] . In fact, we currently use these criteria to diagnose PCH.
To conclude, we agree with Dr Ikegami that PCH is a potential complication of a TVR-based antiviral regimen. For as long as an interferon-based regimen is used after LT, hepatologists should be alert to possibilities of PHC occurrence. Close monitoring of drug-drug interactions is warranted, particularly soon after PI initiation and also at the time of PI discontinuation. We also think that using stringent criteria based on serological markers and histological features is crucial to preventing a misdiagnosis of PHC.
